MiSight 1 day contact lenses are the first FDA-approved soft contact lens proven to slow myopia progression in children. Learn how they work, who qualifies, and what to expect at ProVision Eye Associates in Blue Bell, PA.
What Are MiSight 1 Day Contact Lenses?
MiSight 1 day contact lenses, made by CooperVision, are the first and only FDA-approved soft contact lens specifically designed to slow the progression of myopia (nearsightedness) in children. Approved in 2019, MiSight uses a patented dual-focus optical design that simultaneously corrects a child's current prescription while sending a signal to the eye that slows the axial elongation responsible for worsening myopia.
At [ProVision Eye Associates](/services/myopia-control) in Blue Bell, PA, MiSight is one of several evidence-based myopia control options we offer — alongside Ortho-K overnight lenses, Stellest HALT spectacle lenses, and low-dose atropine therapy.
Why Does Myopia Progression Matter?
Myopia is not just an inconvenience that glasses can fix. Each diopter of myopia increases the risk of serious eye disease later in life. Children with high myopia (greater than -6.00 diopters) face significantly elevated risks of retinal detachment (up to 10 times higher risk), myopic macular degeneration, glaucoma (3 times higher risk), and earlier onset cataracts. The goal of myopia control is to keep a child's prescription as low as possible at adulthood, reducing their lifetime risk of these vision-threatening complications.
How Do MiSight Lenses Work?
MiSight lenses use ActivControl Technology — a dual-focus design with alternating correction and treatment zones across the lens surface. The correction zones focus light precisely on the retina, providing clear distance vision. The treatment zones focus light in front of the peripheral retina, creating a myopic defocus signal that tells the eye to stop growing. This peripheral defocus signal is the key mechanism. Research has shown that the eye's growth is guided in part by where light focuses on the peripheral retina.
What Does the Research Show?
MiSight has one of the strongest evidence bases of any myopia control treatment available. The pivotal 3-year clinical trial demonstrated a 59% reduction in myopia progression and a 52% reduction in axial elongation compared to standard single-vision contact lenses. After 6 years of continuous wear, children who wore MiSight from the start showed significantly less myopia than those who switched from standard lenses.
Who Is a Good Candidate for MiSight?
MiSight is FDA-approved for children aged 8–12 years at the initiation of treatment, with myopia between -0.75 and -4.00 diopters. The ideal candidate is a child who has been diagnosed with myopia and is showing progression, is motivated to wear daily disposable contact lenses consistently, and has parents committed to the treatment program and follow-up schedule.
Comparing Myopia Control Options
| Treatment | Mechanism | Best For | Wear Schedule |
|---|---|---|---|
| MiSight 1 day | Peripheral defocus | Ages 8–12, mild-moderate myopia | Daily disposable contact |
| Ortho-K | Corneal reshaping | All ages, active kids | Overnight only |
| Stellest HALT | Peripheral defocus | Spectacle wearers | Daily spectacle lens |
| Atropine drops | Biochemical signal | Adjunct therapy | Nightly eye drop |
Schedule a Myopia Control Consultation in Blue Bell, PA
If your child's prescription has been increasing year over year, now is the time to act. Myopia control is most effective when started early. ProVision Eye Associates serves families from Blue Bell, Lansdale, Ambler, Horsham, and throughout Montgomery County.
[Schedule a myopia control consultation today](/schedule) and give your child the best chance at healthy vision for life.
